DECAMETHOXIN: NEBULIZER THERAPY OF INFECTIOUS EXACERBATION OF CHRONIC BRONCHITIS
Journal Title: Астма и Аллергия - Year 2019, Vol 1, Issue 3
Abstract
Exacerbation of chronic bronchitis (CB) is a risk factor for death, hospitalizations, respiratory symptoms worsening, limitation of physical activity and disability of the patients. The causes of 60 to 80 % of all exacerbations of CB are infectious agents. The aim: To study the spectrum of the infectious agents of the chronic bronchitis exacerbation and to improve the effectiveness of treatment of patients with this disease. Materials and methods. For the study of the infectious agents of the chronic bronchitis exacerbation, virological and microbiological studies of sputum, washings, or smears from the nasal mucosa were performed in 100 patients with infectious exacerbation of СB. 146 patients participated in the study of the treatment efficacy, which was divided into three groups depending on the volume of anti-infective therapy (group I — antibacterial drug + mucoregulator, group II — antibiotic, mucoregulator + inhalation 0.02 % decamethoxin solution, group III — mucoregulator + inhalation 0.02 % decamethoxin solution). The effectiveness of the treatment was evaluated on days 3–5 (visit 2) and 10–14 day s (visit 3) from the beginning. Results. In the study of the exacerbation agents of the CB, in 44.0 % of cases viruses, in 35.0 % — bacteria, and 21.0 % — virus-bacterial associations were identified. Under the influence of treatment, the number of patients who had a severe cough before the 2 visits, in group I was 9.5 %, in the second — 10.5 %, in the third — 5.6 %. At the end of treatment, moderate cough persisted in 41.5 % of patients of group I, 7.0 % of patients of group II patients and 22.2 % of group III patients. By visit 3, normalizati on of body temperature in the observation groups was achieved in 73.6 % of patients of the first group, 89.5 % of patients of the second group and 72.2 % — of the third group. Hyperemia of the throat and difficulty in nasal breathing in patients of group II by the end of treatment decreased in a greater number (54.4 %) of patients compared with patients of group I (30.2 %), p < 0.05. Symptoms of rhinitis in patients of group III by the end of treatment decreased in more patients (52.7 %) compared with patients in group I (32.1 %), p < 0.05. The total duration of antibacterial therapy in patients in group 1 was on average (7.8 ± 0.8) days, and in patients in group 2 — (5.7 ± 0.6) days (p < 0.05). Conclusions. The additional inhaled use of decamethoxin 0.02 % sterile solution in the complex treatment of patients with infectious exacerbation of СB allowed to reduce the severity and duration (on average by 1–2 days) of the manifestations of intoxication and catarrhal phenomena. Nebulizer therapy with 0.02 % decamethoxin sterile solution solution reduces the duration of infectious exacerbation of СB by 1.6 days, reduces the duration of antibiotic use by 2 days, and also avoids the unnecessary administration of antibacterial drugs in the mild course of infectious exacerbation of СB.
Authors and Affiliations
M. I. Gumeniuk, O. V. Denysova, G. L. Gumeniuk, S. G. Opimakh, V. І. Ignatieva
Keywords
Related Articles
- EP ID EP655802
- DOI 10.31655/2307-3373-2019-3-17-28
- Views 134
- Downloads 0
WORLD ASTHMA DAY: A MIRACLE REASON TO ACTIVATE EFFORTS
Bronchial asthma is among the most common noncommunicable diseases, which affects more than 300 million people around the world. The article describes the international initiative Open Access to scientific information an...
RESPIRATORY TRAININGS WITH POSITIVE END-EXPIRATORY PRESSURE AND LIFE QUALITY OF ELDERLY PATIENTS WITH COPD
Assessment of the quality of life allows individualizing treatment measures and increasing treatment efficacy. The chronic obstructive pulmonary disease (COPD) decreases the functional pulmonary capacities and...
EVALUATION OF THE EFFICACY AND SAFETY OF COMBINED USE OF FORMOTEROL AND FLUTICASONE PROPIONATE IN THE TREATMENT OF PATIENTS WITH BRON-CHIAL ASTHMA AND COMORBID CORONARY HEART DISEASE
TAim: to evaluate the clinical efficacy and safety of the use of formoterol (Zafiron medicine, «Adamed Pharma S.A» pharmaceutical company) and fluticasone propionate (Flutixon medicine, «Adamed Pharma S.A» ph...
DIAGNOSTIC VALUE OF METHODS FOR SENSITIZATION DETERMINATION IN PEOPLE WITH ALLERGIC RHINITIS (REVIEW OF LITERATURE AND OWN DAT
Objective was to review the literature on the diagnostic value of various methods for determining sensitization in patients with allergies, to study the parameters of the specificity and sensitivity of skin testing and l...
Agreement between standard methods of Food hypersensitivity diagnostics IN CHILDREN
The objective was to study agreement between standard methods of food hypersensitivity diagnostics. Materials and methods. 424 patients aged 26,3 (12,1; 54,25) months were included in the study. Methods included skin pri...